Antidiabetic drug metformin suppresses tumorigenesis through inhibition of mevalonate pathway enzyme HMGCS1

[1]  K. Gadde,et al.  Effect of Metformin and Lifestyle Interventions on Mortality in the Diabetes Prevention Program and Diabetes Prevention Program Outcomes Study , 2021, Diabetes Care.

[2]  Yue-Qi Cao,et al.  Pan‐cancer analysis reveals the oncogenic role of 3‐hydroxy‐3‐methylglutaryl‐CoA synthase 1 , 2021, Cancer reports.

[3]  Xiao-Qiu Li,et al.  Alteration of Cholesterol Metabolism by Metformin Is Associated With Improved Outcome in Type II Diabetic Patients With Diffuse Large B-Cell Lymphoma , 2021, Frontiers in Oncology.

[4]  Juan Du,et al.  HMGCS1 drives drug-resistance in acute myeloid leukemia through endoplasmic reticulum-UPR-mitochondria axis. , 2021, Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie.

[5]  H. El‐Serag,et al.  Global epidemiology of NAFLD-related HCC: trends, predictions, risk factors and prevention , 2020, Nature Reviews Gastroenterology & Hepatology.

[6]  Yi-qing Wang,et al.  Metformin reverses chemoresistance in non-small cell lung cancer via accelerating ubiquitination-mediated degradation of Nrf2 , 2020, Translational lung cancer research.

[7]  T. Kim,et al.  Metformin Suppresses Cancer Stem Cells through AMPK Activation and Inhibition of Protein Prenylation of the Mevalonate Pathway in Colorectal Cancer , 2020, Cancers.

[8]  E. Ziv,et al.  NRF2 Dysregulation in Hepatocellular Carcinoma and Ischemia: A Cohort Study and Laboratory Investigation. , 2020, Radiology.

[9]  Hyunjin Park,et al.  The Clinicopathological and Prognostic Significance of Nrf2 and Keap1 Expression in Hepatocellular Carcinoma , 2020, Cancers.

[10]  Christian M. Metallo,et al.  PKCλ/ι Loss Induces Autophagy, Oxidative Phosphorylation, and NRF2 to Promote Liver Cancer Progression. , 2020, Cancer cell.

[11]  D. Ye,et al.  Nrf2 activation ameliorates mechanical allodynia in paclitaxel-induced neuropathic pain , 2020, Acta Pharmacologica Sinica.

[12]  A. Tsatsakis,et al.  Potential Applications of NRF2 Modulators in Cancer Therapy , 2020, Antioxidants.

[13]  A. Schulze,et al.  Greasing the Wheels of the Cancer Machine: The Role of Lipid Metabolism in Cancer. , 2019, Cell metabolism.

[14]  Gregory J. Gores,et al.  A global view of hepatocellular carcinoma: trends, risk, prevention and management , 2019, Nature Reviews Gastroenterology & Hepatology.

[15]  D. Calvisi,et al.  Cholesterol biosynthesis supports the growth of hepatocarcinoma lesions depleted of fatty acid synthase in mice and humans , 2019, Gut.

[16]  A. Huttenlocher,et al.  Metformin modulates innate immune-mediated inflammation and early progression of NAFLD-associated hepatocellular carcinoma in zebrafish. , 2019, Journal of hepatology.

[17]  Darjus F. Tschaharganeh,et al.  p53 Represses the Mevalonate Pathway to Mediate Tumor Suppression , 2019, Cell.

[18]  N. Hagiwara,et al.  Mevalonate pathway blockage enhances the efficacy of mTOR inhibitors with the activation of retinoblastoma protein in renal cell carcinoma. , 2018, Cancer letters.

[19]  Masayuki Yamamoto,et al.  Genetic inactivation of Nrf2 prevents clonal expansion of initiated cells in a nutritional model of rat hepatocarcinogenesis. , 2018, Journal of hepatology.

[20]  Ronghua Li,et al.  Metformin Promotes HaCaT Cell Apoptosis through Generation of Reactive Oxygen Species via Raf-1-ERK1/2-Nrf2 Inactivation , 2018, Inflammation.

[21]  Wei Jia,et al.  Bile acid–microbiota crosstalk in gastrointestinal inflammation and carcinogenesis , 2018, Nature Reviews Gastroenterology & Hepatology.

[22]  R. Horst,et al.  Metabolic Induction of Trained Immunity through the Mevalonate Pathway , 2018, Cell.

[23]  Qiulian Wu,et al.  MYC-Regulated Mevalonate Metabolism Maintains Brain Tumor-Initiating Cells. , 2017, Cancer research.

[24]  T. Iwakuma,et al.  DNAJA1 controls the fate of misfolded mutant p53 through the mevalonate pathway , 2016, Nature Cell Biology.

[25]  M. Ferrer,et al.  Small Molecule Inhibitor of NRF2 Selectively Intervenes Therapeutic Resistance in KEAP1-Deficient NSCLC Tumors. , 2016, ACS chemical biology.

[26]  M. C. Archer,et al.  The interplay between cell signalling and the mevalonate pathway in cancer , 2016, Nature Reviews Cancer.

[27]  F. Wondisford,et al.  Metformin action: concentrations matter. , 2015, Cell metabolism.

[28]  R. Loomba.  Rationale for conducting a randomized trial to examine the efficacy of metformin in improving survival in cirrhosis: Pleiotropic effects hypothesis , 2014, Hepatology.

[29]  J. Hayes,et al.  The Nrf2 regulatory network provides an interface between redox and intermediary metabolism. , 2014, Trends in biochemical sciences.

[30]  M. Murad,et al.  Statins are associated with a reduced risk of hepatocellular cancer: a systematic review and meta-analysis. , 2013, Gastroenterology.

[31]  J. Shieh,et al.  Metformin decreases hepatocellular carcinoma risk in a dose-dependent manner: population-based and in vitro studies , 2012, Gut.

[32]  A. Levine,et al.  Mutant p53 Disrupts Mammary Tissue Architecture via the Mevalonate Pathway , 2012, Cell.

[33]  I. Ben-Sahra,et al.  Metformin, independent of AMPK, induces mTOR inhibition and cell-cycle arrest through REDD1. , 2011, Cancer research.

[34]  S. Nilsson,et al.  Mevalonate pathway inhibitors affect anticancer drug-induced cell death and DNA damage response of human sarcoma cells. , 2011, Cancer letters.

[35]  S. Gambhir,et al.  MYC phosphorylation, activation, and tumorigenic potential in hepatocellular carcinoma are regulated by HMG-CoA reductase. , 2011, Cancer research.

[36]  D. Hanahan,et al.  Hallmarks of Cancer: The Next Generation , 2011, Cell.

[37]  Tsutomu Ohta,et al.  Cancer related mutations in NRF2 impair its recognition by Keap1-Cul3 E3 ligase and promote malignancy , 2008, Proceedings of the National Academy of Sciences.

[38]  I. Ben-Sahra,et al.  The antidiabetic drug metformin exerts an antitumoral effect in vitro and in vivo through a decrease of cyclin D1 level , 2008, Oncogene.

[39]  Nahum Sonenberg,et al.  Metformin is an AMP kinase-dependent growth inhibitor for breast cancer cells. , 2006, Cancer research.

[40]  C. B. Pickett,et al.  Phosphorylation of Nrf2 at Ser-40 by Protein Kinase C Regulates Antioxidant Response Element-mediated Transcription* , 2002, The Journal of Biological Chemistry.

[41]  Xavier Messeguer,et al.  PROMO: detection of known transcription regulatory elements using species-tailored searches , 2002, Bioinform..

[42]  S. Bicciato,et al.  Mechanical cues control mutant p53 stability through a mevalonate–RhoA axis , 2017, Nature Cell Biology.